A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma

European Respiratory Journal

Volumn 36, Issue 5, 2010, Pages 1099-1105

  Tabata, C ^a   Hirayama, N ^a   Tabata, R ^b   Yasumitsu, A ^a   Yamada, S ^a   Murakami, A ^a   Iida, S ^a   Tamura, K ^a   Fukuoka, K ^a   Kuribayashi, K ^a   Terada, T ^a   Nakano, T ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

Cytokines; Pleural disease; Serum marker

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ASBESTOS;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASBESTOSIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MAJOR CLINICAL STUDY; MESENCHYME CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURA PLAQUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ASBESTOSIS; BIOLOGICAL MARKERS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FIBROBLASTS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, SCID; NEOPLASMS, MESOTHELIAL; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTOR, TIE-2; RNA, MESSENGER;

EID: 78349261563     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00154009     Document Type: Article

References (21)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-271.
4. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980; 15: 2736-2740. (Pubitemid 11210245)
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644. (Pubitemid 46606305)
6. Nowak AK, Lake RA, Kindler HL, et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002; 29: 82-96.
7. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
8. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573. (Pubitemid 41434635)
9. Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007; 179: 708-714. (Pubitemid 46986590)
10. Tabata C, Kubo H, Tabata R, et al. All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system. Am J Physiol Lung Cell Mol Physiol 2006; 290: 597-606. (Pubitemid 43725105)
11. Tabata C, Kadokawa Y, Tabata R, et al. All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 1352-1360. (Pubitemid 44913037)
12. Tabata C, Tabata R, Hirayama N, et al. All-trans-retinoic acid inhibits tumoir growth of malignant pleural mesothelioma in mice. Eur Respir J 2009; 34: 1159-1167.
13. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-1128.
14. Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009; 100: 1175-1183.
15. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-1160.
16. Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999; 25: 25-32.
17. Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987; 59: 2104-2107.
18. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
19. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693.
20. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463.
21. Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003; 124: 1916-1923.